CLDX
Celldex Therapeutics Inc
37.90$
-0.9%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Cash Flow
Celldex Therapeutics Inc (CLDX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -211 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.7 | -7.7 | -8.9 | -8.5 | -4.4 | -21 | -17 | -12 | -10 | -6.0 | 27 | -19 | 18 | -30 | -30 | -36 | -50 | -68 | -102 | -99 | -113 | -100 | -75 | -46 | -40 | -61 | -104 | -107 | -158 | -211 | |
| 0.5 | 0.4 | 1.0 | 2.0 | 1.3 | 2.3 | 1.6 | 1.5 | 1.7 | 2.1 | 2.1 | 2.7 | 2.5 | 3.5 | 5.9 | 4.2 | 3.1 | 2.9 | 3.4 | 4.0 | 4.1 | 5.3 | 3.8 | 4.9 | 3.9 | 3.1 | 1.4 | 3.0 | 3.2 | -2.5 | |
| – | – | – | – | – | – | – | 115 | 328 | 538 | 1,627 | 360 | 4,816 | 3.1 | 2.8 | 2.3 | 2.3 | 4.5 | 6.9 | 13 | 15 | 12 | 8.1 | 4.6 | 3.9 | 9.0 | 16 | 24 | 34 | 36 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.3 | 2.2 | 4.5 | 6.8 | 13 | 15 | 0.3 | 89 | 5.1 | 16 | 7.6 | 9.6 | – | – | – | |
| -0.8 | -0.2 | -2.8 | 0.7 | 7.2 | -0.4 | -4.5 | -1.8 | 1.1 | 10.0 | 44 | -1.3 | 43 | 0.9 | -37 | 2.4 | 4.4 | 7.7 | 6.1 | 11 | -6.6 | -12 | -15 | -4.3 | -0.3 | -1.1 | -3.9 | 13 | -22 | 14 | |
| 0.6 | 0.1 | 0.3 | 0.7 | 0.2 | 0.6 | 0.6 | 0.2 | 0.0 | 0.0 | 9.3 | 5.0 | 1.3 | 0.5 | 2.1 | 0.5 | 0.3 | 4.2 | 1.9 | 4.9 | 2.8 | 1.8 | 0.8 | 0.7 | 1.6 | 1.2 | 1.8 | 1.8 | 1.9 | 2.7 | |
| -0.2 | 1.5 | 7.6 | 3.3 | -1.0 | -0.8 | -0.8 | -2.2 | -1.7 | -2.2 | -9.3 | -5.7 | 10 | 45 | -16 | -2.2 | -17 | -77 | -41 | -50 | 69 | 46 | 30 | 17 | -98 | -216 | 90 | -106 | -290 | 209 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -0.1 | -0.1 | – | – | – | – | – | – | – | 36 | 84 | 296 | 1.2 | 193 | 14 | 51 | 29 | 16 | 171 | 272 | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -7.6 | -4.0 | -12 | – | – | – | – | – | – | – | 0.0 | 0.0 | – | – | – | |
| 10 | – | 3.7 | 10.0 | 42 | 14 | -0.1 | 9.1 | 25 | -0.1 | -0.2 | -0.2 | 11 | -2.5 | 11 | 28 | 80 | 290 | 1.2 | 193 | 14 | 51 | 29 | 16 | 171 | 272 | 4.1 | 218 | 441 | 2.4 | |
| 0.3 | -6.2 | 2.5 | 4.7 | 37 | -7.5 | -18 | -4.8 | 13 | -8.3 | 17 | -25 | 39 | 13 | -36 | -9.4 | 13 | 145 | -141 | 44 | -30 | -2.2 | -16 | -13 | 33 | -4.7 | -9.7 | 5.4 | -6.5 | 0.5 | |
| -10 | -7.8 | -9.2 | -9.2 | -4.6 | -21 | -17 | -12 | -10 | -6.0 | 18 | -24 | 17 | -30 | -32 | -36 | -50 | -72 | -103 | -104 | -116 | -102 | -76 | -47 | -42 | -62 | -106 | -109 | -160 | -214 |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.